Showing results (21-30 of 41) with videos related to
Sort By:
Pageof 5
Scientific Reports|November 8, 2023
Efficacy of second-line chemotherapy after treatment with gemcitabine plus nab-paclitaxel or FOLFIRINOX in patients with metastatic pancreatic cancerMasaru Fukahori, Yoshinobu Okabe, Mototsugu Shimokawa, et al.Scientific Reports|May 31, 2023
C-reactive protein/albumin ratio is the most significant inflammatory marker in unresectable pancreatic cancer treated with FOLFIRINOX or gemcitabine plus nab-paclitaxelTsuyoshi Shirakawa, Akitaka Makiyama, Mototsugu Shimokawa, et al.Oncology|October 4, 2022
Multicenter Retrospective Analysis of Original versus Modified FOLFIRINOX in Metastatic Pancreatic Cancer: Results of the NAPOLEON StudyJunichi Nakazawa, Nobuhiro Tsuruta, Mototsugu Shimokawa, et al.Journal of Geriatric Oncology|July 3, 2021
Gemcitabine plus nab-paclitaxel in older patients with metastatic pancreatic cancer: A post-hoc analysis of the real-world data of a multicenter study (the NAPOLEON study)Futa Koga, Yasunori Kawaguchi, Mototsugu Shimokawa, et al.Cancer Science|January 19, 2019
Phase II trial of aflibercept with FOLFIRI as a second-line treatment for Japanese patients with metastatic colorectal cancerTadamichi Denda, Daisuke Sakai, Tetsuya Hamaguchi, et al.International Journal of Clinical Oncology|July 21, 2022
Primary tumor location as a predictor of survival in patients with RAS wild-type colorectal cancer who receive molecularly targeted drugs as first-line therapy: a multicenter real-world observational study by the Japanese Society for Cancer of the Colon and RectumTakahiko Ito, Atsuo Takashima, Kentaro Yamazaki, et al.International Journal of Clinical Oncology|March 4, 2026
Comparison of first-line cetuximab and panitumumab plus doublet chemotherapies for left-sided colorectal cancer: a multicenter real-world observational study by the Japanese Society for Cancer of the Colon and RectumRyosuke Kawagoe, Toshikazu Moriwaki, Kentaro Yamazaki, et al.Therapeutic Advances in Medical Oncology|April 29, 2026
Predictors of prolonged progression-free survival in patients with unresectable or recurrent pancreatic cancer treated with nanoliposomal irinotecan with fluorouracil and folinic acid (NAPOLEON-2 study)Yasunori Kawaguchi, Kohei Hayashi, Mototsugu Shimokawa, et al.Asia-Pacific Journal of Clinical Oncology|November 4, 2025
Nanoliposomal Irinotecan With Fluorouracil and Folinic Acid in Older Versus Younger Patients With Unresectable Pancreatic Cancer: The Multicenter NAPOLEON-2 StudyAtsuko Kakihara, Shigeyuki Takeshita, Mototsugu Shimokawa, et al.BMC Cancer|October 22, 2025
Impact of biliary drainage for unresectable pancreatic cancer treated with nanoliposomal irinotecan with fluorouracil and folinic acid: retrospective results from the NAPOLEON-2 studyKazuo Nishikawa, Taiga Otsuka, Mototsugu Shimokawa, et al.Pageof 5